** U.S.-listed shares of Israel based drug developer PainReform PRFX.O fall 18.4% to $4 premarket
** Co says its lead experimental pain relief treatment, PRF-110, did not meet the main goal of a late-stage study
** Co announced interim data from the late-stage study in November where it was testing PRF-110 to study the effect of the treatment in reducing pain over 72 hours
** Co had previously said that data from the late-stage pertaining to the last 24-hour period of the 72-hour study was unclear
** After further investigation co says the data could not be clarified to satisfy the study's main goal
** Co says despite setback, it has started R&D activities to better understand the effects of the treatment "to potentially resolve this issue to support future clinical trials"
** PRF-110 was tested to provide prolonged pain relief while reducing the need for opioids, in the post-surgical setting
** Up to last close, stock down 92.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.